Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
22 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Eczema severity linked to mental health problems in schoolchildren

28 Oct 2018

Schoolchildren with severe eczema are at heightened risk of mental health problems including emotional symptoms, conduct problems, hyperactivity/inattention and peer problems, a study has found. 

Researchers looked at 9,954 schoolchildren in the 2nd to the 8th grades from the ToMMo Child Health Study, a cross-sectional survey in Miyagi Prefecture, Japan.

Eczema status was evaluated according to the International Study of Asthma and Allergies in Childhood (ISAAC) Eczema Symptom Questionnaire. Mental health problems were identified using the clinical ranges of Strengths and Difficulties Questionnaire (SDQ) total difficulties scores and the four SDQ subcategories of emotional symptoms, conduct problems, hyperactivity/inattention, and peer problems.

Mean SDQ total difficulties scores significantly increased with worsening eczema status (p≤0.004 for trend). The odds ratios for SDQ total difficulties were 1.51 (95 percent CI, 1.31–1.74) for mild/moderate eczema and 2.63 (1.91–3.63) for severe eczema (p<0.001 for trend) vs normal eczema.

Similar results were obtained for the four SDQ subcategories. Specifically, greater eczema severity was associated with increased emotional symptoms, conduct problems, hyperactivity/inattention and peer problems (p≤0.017 for all).

In light of the finding that the presence of eczema in schoolchildren is associated with multiple psychiatric symptoms, researchers advised that physicians treating this population pay attention to potential mental health problems.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
22 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.